Extended stage small cell lung cancer patients confirmed histologically in full research hub

A Phase II, open label, single arm, multicentre study on THOracic Radiotherapy in Extensive Stage SCLC patients submitted to first line CHT-RT plus Durvalumab (MEDI4736)

This study is looking at a new way to treat extensive small cell lung cancer. It combines standard chemotherapy with radiotherapy and a drug called Durvalumab. Researchers want to see if this combination can help people live longer without their cancer getting worse.